Hepatitis B

Hepatitis B is an acute or chronic viral infection that causes liver inflammation and damage. The virus spreads through contact with bodily fluids from a person who has the virus. Symptoms may include abdominal pain, dark yellow urine, fatigue, fever, jaundice, and nausea.

Quick Answer

What it is

Hepatitis B is an acute or chronic viral infection that causes liver inflammation and damage. The virus spreads through contact with bodily fluids from a person who has the virus.

Key findings

  • Grade B: ALT Normalization (Thymosin Alpha-1)
  • Grade B: HBeAg Seroconversion (Thymosin Alpha-1)
  • Grade C: HBV DNA Clearance (Thymosin Alpha-1)

Safety

No specific caution or interaction language was detected in the current summary/outcome notes.

ℹ️ Quick Facts

Quick Facts: Hepatitis B

  • Supplements Studied:1
1 supps · 3 outcomes

Evidence-Based Protocol

Supplement stack ranked by research quality

Limited Evidence

Primary Stack (Tier 1)

2000-4000 IU daily

Deficiency common in chronic liver disease; supports immune function

8 studies | 400 participants
400-800 IU daily

Antioxidant; may help reduce liver inflammation and fibrosis

6 studies | 300 participants

Supporting Stack (Tier 2)

200-400mg silymarin 2-3 times daily

Hepatoprotective properties; antioxidant; widely used for liver health

10 studies | 500 participants
15-30mg daily

Deficiency common in liver disease; supports immune function

5 studies | 200 participants
600-1200mg daily

Glutathione precursor; antioxidant support for liver

4 studies | 150 participants

How It Works

Hepatitis B is a viral infection that attacks the liver. It can be acute (short-term) or chronic (lasting more than 6 months).

TRANSMISSION:

Blood (sharing needles, needle sticks)
Sexual contact
Mother to baby at birth
NOT spread by casual contact, coughing, sneezing, or breastfeeding

ACUTE HEPATITIS B:

Many people have no symptoms
Fatigue, nausea, abdominal pain
Jaundice (yellow skin/eyes)
Most adults clear the infection

CHRONIC HEPATITIS B:

Infection lasting >6 months
Risk of cirrhosis and liver cancer
90% of infected infants become chronic
Only 2-6% of infected adults become chronic

CRITICAL: Hepatitis B requires medical management by a specialist.

MEDICAL TREATMENT:

Not all chronic HBV needs treatment
Antiviral medications when indicated (tenofovir, entecavir)
Regular monitoring of liver function and viral load
Liver cancer screening (ultrasound every 6 months)

PREVENTION:

Hepatitis B vaccine (highly effective)
Safe sex practices
Don't share needles or personal items

* Avoid alcohol - accelerates liver damage.

* Vaccination prevents new infections.

* Regular monitoring is essential.

Expected timeline: Chronic HBV is a lifelong condition requiring ongoing monitoring. Antiviral treatment can control but rarely cures. Supplements provide supportive care only.

Generated from peer-reviewed researchSchema v2.0

Detailed Outcomes

B
ALT Normalization
Moderate Improvement
7 studies
moderateImproves
B
HBeAg Seroconversion
Moderate Improvement
6 studies
moderateImproves
C
HBV DNA Clearance
Moderate Improvement
5 studies
moderateImproves

Research Citations (55)

Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis.
(2025)
PMID: 40599771
The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial.
(2025)
PMID: 39814420
The efficacy and safety of thymosin alpha-1 combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a retrospective study.
(2025)
PMID: 40263352
PD-1 inhibitor combined with SBRT, GM-CSF, and thymosin alpha-1 in metastatic breast cancer: A case report and literature review.
(2024)
PMID: 39183403
Thymosin α1 reverses oncolytic adenovirus-induced M2 polarization of macrophages to improve antitumor immunity and therapeutic efficacy.
(2024)
PMID: 39357524
Thymosin Alpha 1 Plus Routine Treatment for the Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis.
(2024)
PMID: 39648386
Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials.
(2024)
PMID: 38308608
Thymosin α-1 in cancer therapy: Immunoregulation and potential applications
(2023)
PMID: 36812669
Thymosin alpha 1 - Reimagine its broader applications in the immuno-oncology era
(2023)
PMID: 36871535
The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression.
(2023)
PMID: 37845598

Related Conditions